Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Trump Administration Releases New UFO Files and Apollo Mission Records 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
